Pacer Advisors Inc. Boosts Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Pacer Advisors Inc. grew its stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 47.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,676,200 shares of the company's stock after purchasing an additional 1,183,558 shares during the quarter. Pacer Advisors Inc. owned approximately 4.32% of Progyny worth $63,414,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Quarry LP raised its stake in shares of Progyny by 1,900.0% in the 2nd quarter. Quarry LP now owns 880 shares of the company's stock valued at $25,000 after purchasing an additional 836 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Progyny during the second quarter worth about $44,000. GAMMA Investing LLC raised its stake in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after acquiring an additional 1,246 shares during the period. Nisa Investment Advisors LLC raised its stake in Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after acquiring an additional 1,526 shares during the period. Finally, Mendota Financial Group LLC bought a new position in Progyny in the 3rd quarter worth about $56,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Insider Transactions at Progyny

In other Progyny news, Chairman David J. Schlanger purchased 150,000 shares of the company's stock in a transaction on Thursday, December 26th. The shares were purchased at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the purchase, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. This represents a 191.65 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Peter Anevski bought 209,500 shares of the stock in a transaction dated Monday, December 23rd. The shares were purchased at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the transaction, the chief executive officer now directly owns 441,463 shares of the company's stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

Progyny Stock Down 1.4 %

NASDAQ PGNY traded down $0.34 during trading on Friday, reaching $23.20. 1,260,081 shares of the stock traded hands, compared to its average volume of 1,999,784. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of 40.00, a price-to-earnings-growth ratio of 2.32 and a beta of 1.31. The stock's 50-day moving average price is $17.46 and its 200 day moving average price is $19.27. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The company had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same period in the prior year, the company earned $0.16 EPS. The firm's revenue was up 2.0% on a year-over-year basis. Analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on PGNY shares. Bank of America decreased their price objective on shares of Progyny from $22.00 to $21.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. Barclays decreased their price objective on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, November 14th. Canaccord Genuity Group decreased their price objective on shares of Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a report on Wednesday, November 13th. JPMorgan Chase & Co. increased their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday. Finally, Truist Financial restated a "hold" rating and set a $19.00 target price (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Progyny has an average rating of "Hold" and a consensus price target of $25.50.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.